- Home
- BCTXZ vs MTX Comparison
BCTXZ vs MTX Comparison
Compare BCTXZ & MTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTXZ
- MTX
- Stock Information
- Founded
- BCTXZ N/A
- MTX 1968
- Country
- BCTXZ Canada
- MTX United States
- Employees
- BCTXZ 12
- MTX N/A
- Industry
- BCTXZ
- MTX Major Chemicals
- Sector
- BCTXZ
- MTX Industrials
- Exchange
- BCTXZ Nasdaq
- MTX Nasdaq
- Market Cap
- BCTXZ N/A
- MTX N/A
- IPO Year
- BCTXZ N/A
- MTX 1992
- Fundamental
- Price
- BCTXZ $0.94
- MTX $56.00
- Analyst Decision
- BCTXZ
- MTX Strong Buy
- Analyst Count
- BCTXZ 0
- MTX 2
- Target Price
- BCTXZ N/A
- MTX $80.00
- AVG Volume (30 Days)
- BCTXZ N/A
- MTX 292.4K
- Earning Date
- BCTXZ N/A
- MTX 04-24-2025
- Dividend Yield
- BCTXZ N/A
- MTX 0.78%
- EPS Growth
- BCTXZ N/A
- MTX N/A
- EPS
- BCTXZ N/A
- MTX N/A
- Revenue
- BCTXZ N/A
- MTX $2,075,800,000.00
- Revenue This Year
- BCTXZ N/A
- MTX $2.19
- Revenue Next Year
- BCTXZ N/A
- MTX $4.80
- P/E Ratio
- BCTXZ N/A
- MTX N/A
- Revenue Growth
- BCTXZ N/A
- MTX N/A
- 52 Week Low
- BCTXZ N/A
- MTX $49.54
- 52 Week High
- BCTXZ N/A
- MTX $90.30
- Technical
- Relative Strength Index (RSI)
- BCTXZ N/A
- MTX 49.32
- Support Level
- BCTXZ N/A
- MTX $51.87
- Resistance Level
- BCTXZ N/A
- MTX $53.96
- Average True Range (ATR)
- BCTXZ 0.00
- MTX 2.16
- MACD
- BCTXZ 0.00
- MTX 0.59
- Stochastic Oscillator
- BCTXZ 0.00
- MTX 66.19
About BCTXZ BriaCell Therapeutics Corp. Warrant
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.